Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6593571 | 0.98 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL6980495 | 0.84 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL7457314 | 0.79 | CSNK2A1 (0.37) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL28925250 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CYP3A4CSNK2A1IMPDH2 | |
| SCHEMBL9812750 | 0.73 | CYP3A4 (0.36) | ALDH1A1CYP3A4TDP1TP53CSNK2A1 | |
| SCHEMBL462653 | 0.71 | HTR1A (0.36) | CSNK2A1 | |
| SCHEMBL7696358 | 0.70 | IMPDH2 (0.38) | ALDH1A1CYP3A4TSHRCSNK2A1IMPDH2 | |
| Hydrochloric Acid SCHEMBL5395885 | 0.70 | HTR1A (0.36) | CSNK2A1 | |
| SCHEMBL7461800 | 0.69 | CYP3A4 (0.41) | ALDH1A1CYP3A4TSHRTDP1CSNK2A1 | |
| SCHEMBL5795534 | 0.69 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRCSNK2A1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1156803-A4 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1305309-A1 | LACTAM INHIBITORS OF FACTOR XA WHICH ARE USEFUL FOR THE TREATMENT OF THROMBOSIS | Bristol-Myers Squibb Company (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6511973-B2 | Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses | BRISTOL-MYERS SQUIBB CO. | 2003-01-28 | — | — | US | disclosed |
| US-20020045616-A1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-18 | — | — | US | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2002010159-A1 | LACTAM INHIBITORS OF FACTOR XA WHICH ARE USEFUL FOR THE TREATMENT OF THROMBOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1156803-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6297233-B1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
| WO-2000047207-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | ALDH1A1 2640/4885CYP3A4 190/4885TSHR 1530/4885 |
| US-20020045616-A1 | Lactam inhibitors of FXa and method | F11, TFPI, F2 | ALDH1A1 2115/4885CYP3A4 405/4885TSHR 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.